JS-K inhibits human MM cell growth in vivo. NIH III mice were inoculated subcutaneously in the flank with 3 × 107 OPM1 cells. When tumors became palpable, JS-K (4 μmol/kg; n = 9) or vehicle (n = 8) was administered intravenously 3 times per week. (A) JS-K significantly inhibits MM tumor growth compared with the controls. Tumor volumes are represented as means (± SE). (B) JS-K markedly increases survival of the host. Survival was evaluated using Kaplan-Meier curves and log-rank analysis. JS-K significantly increased survival (P = .001) compared with the control group. (C-E). JS-K induces apoptosis in vivo. Mice were killed 4 hours after the last treatment, and tumors were excised for PI (C), TUNEL (D), or activated caspase-3 (E) analysis. Representative images captured at 40 ×/0.60 are shown.
